Insulin glargine

Upadhyay, DK and Palaian, S and Prabhu, M and Shankar, PR and Mishra, P (2008) Insulin glargine. Journal of Institute of Medicine, 30 (1). pp. 72-77.

[img] PDF
Insulin_Glargin_-_JIOM.pdf - Published Version
Restricted to Registered users only

Download (34kB) | Request a copy


Insulin glargine is a long-acting human insulin analog prepared using recombinant DNA technology. It is the first long-acting analog of human insulin to be approved for clinical use. It is administered once daily and has a smooth 24 hour time-action profile that provides effective glycemic control with minimal risk of hypoglycemia. It may be used for children who are 6 years or older. Though the risk for developing hypoglycemia is less, hypoglycemia is still the most commonly reported adverse effect, especially within the first four weeks of therapy after a switching over to insulin glargine. Intravenous administration of this drug is not recommended due to the risk of severe hypoglycemia. The patients prescribed insulin glargine should be thoroughly counseled by the healthcare professionals regarding its safe and effective use. The vials and cartridges of insulin glargine should be stored in a refrigerator between 2 to 8 degrees C.

Item Type: Article
Uncontrolled Keywords: Glargine, Hypoglycemia, Insulin.
Subjects: Medicine > KMC Manipal > Medicine
Depositing User: KMC Manipal
Date Deposited: 15 Mar 2012 06:03
Last Modified: 15 Mar 2012 06:03

Actions (login required)

View Item View Item